CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.310
-0.201 (-13.30%)
At close: Sep 26, 2025, 4:00 PM EDT
1.319
+0.009 (0.70%)
After-hours: Sep 26, 2025, 7:58 PM EDT
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 233 employees as of December 31, 2024. The number of employees increased by 57 or 32.39% compared to the previous year.
Employees
233
Change (1Y)
57
Growth (1Y)
32.39%
Revenue / Employee
$135,468
Profits / Employee
-$201,245
Market Cap
20.30M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 233 | 57 | 32.39% |
Dec 31, 2023 | 176 | -48 | -21.43% |
Dec 31, 2022 | 224 | 48 | 27.27% |
Dec 31, 2021 | 176 | 32 | 22.22% |
Dec 31, 2020 | 144 | 19 | 15.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CASI News
- 1 day ago - CASI Pharmaceuticals Appoints James Huang to Board of Directors - Accesswire
- 19 days ago - CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study - Accesswire
- 24 days ago - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - Accesswire
- 25 days ago - CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors - Accesswire
- 4 weeks ago - CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results - Accesswire
- 4 weeks ago - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 - Accesswire
- 7 weeks ago - CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) - Accesswire
- 2 months ago - CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - Accesswire